Ludwig Oxford research wins Journal for ImmunoTherapy of Cancer’s best basic tumour immunology paper of 2022
15 November 2022
A paper on a therapeutic cancer vaccine from the Van den Eynde lab was singled out for this award celebrating excellence in scientific research.
Mechanistic insights into the ZBP1 inflammatory response
21 October 2022
A collaborative study, led by former Ludwig Oxford group leader Professor Mads Gyrd-Hansen, sheds light on the ZBP1-induced signalling pathway, a pathway which contributes to the viral immune response, including to SARS-CoV-2
Cancer at Oxford
29 September 2022
Barnes Boccellato Schuster-Böckler Song Van den Eynde
Read about how Oxford's experts - including Ludwig Oxford scientists - are leading the way in cancer prevention, detection and treatment as part of the University's Cancer at Oxford series
Ludwig Oxford retreat 2022 – a recap
15 July 2022
Barnes Boccellato Byrne Constantinescu De Val Goding Kriaucionis Lu Mehdipour Moura Alves Ratcliffe Schuster-Böckler Shi Song Van den Eynde
On 13-14th June 2022, the Oxford Branch of the Ludwig Institute for Cancer Research held their annual retreat to discuss key scientific advances within the Branch and beyond.
First patient dosed in phase I/IIa trial of lung cancer immunotherapy vaccine
18 January 2022
A novel immunotherapeutic called VTP-600, based on Ludwig Oxford’s Benoit Van den Eynde’s preclinical research, is being tested in patients for the first time.
Vaccine for treating cancer made possible using Oxford COVID vaccine technology
3 September 2021
A new publication from Benoit Van den Eynde's group has shown that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates in mouse models.
UNIQ summer school 2021
22 July 2021
Kriaucionis Lu Public Engagement Van den Eynde
Three Ludwig Oxford volunteers participate at the 2021 Oncology UNIQ summer school
Clinical trial for therapeutic cancer vaccine
18 December 2019
Research from Benoit Van den Eynde’s laboratory forms the basis of a Phase I/IIa clinical trial.